Adelman Daniel C Md - Net Worth and Insider Trading

Adelman Daniel C Md Net Worth

The estimated net worth of Adelman Daniel C Md is at least $732,913 dollars as of 2024-05-11. Adelman Daniel C Md is the Chief Medical Officer of Aimmune Therapeutics Inc and owns about 21,250 shares of Aimmune Therapeutics Inc (AIMT) stock worth over $732,913. Details can be seen in Adelman Daniel C Md's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Adelman Daniel C Md has not made any transactions after 2020-01-02 and currently still holds the listed stock(s).

Transaction Summary of Adelman Daniel C Md

Adelman Daniel C Md Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Adelman Daniel C Md owns 3 companies in total, including Aimmune Therapeutics Inc (AIMT) , Sunesis Pharmaceuticals Inc (SNSS) , and Viracta Therapeutics Inc (VIRX) .

Click here to see the complete history of Adelman Daniel C Md’s form 4 insider trades.

Insider Ownership Summary of Adelman Daniel C Md

Ticker	Comapny	Transaction Date	Type of Owner
AIMT	Aimmune Therapeutics Inc	2020-10-10	Chief Medical Officer
SNSS	Sunesis Pharmaceuticals Inc	2007-09-13	Sr. VP & Development and CMO
VIRX	Viracta Therapeutics Inc	2005-09-27	Senior VP,Drug Discovery & Dev

Adelman Daniel C Md Latest Holdings Summary

Adelman Daniel C Md currently owns a total of 1 stock. Adelman Daniel C Md owns 21,250 shares of Aimmune Therapeutics Inc (AIMT) as of January 2, 2020, with a value of $732,913.

Latest Holdings of Adelman Daniel C Md

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AIMT	Aimmune Therapeutics Inc	2020-01-02	21,250	34.49	732,913

Holding Weightings of Adelman Daniel C Md

Adelman Daniel C Md Form 4 Trading Tracker

According to the SEC Form 4 filings, Adelman Daniel C Md has made a total of 2 transactions in Aimmune Therapeutics Inc (AIMT) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Aimmune Therapeutics Inc is the sale of 20,000 shares on January 2, 2020, which brought Adelman Daniel C Md around $700,000.

Insider Trading History of Adelman Daniel C Md

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Adelman Daniel C Md Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Adelman Daniel C Md Ownership Network

Ownership Network List of Adelman Daniel C Md

No Data

Ownership Network Relation of Adelman Daniel C Md

Adelman Daniel C Md Owned Company Details

What does Aimmune Therapeutics Inc do?

Who are the key executives at Aimmune Therapeutics Inc?

Adelman Daniel C Md is the Chief Medical Officer of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and See Remarks Douglas T. Sheehy .

Aimmune Therapeutics Inc (AIMT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aimmune Therapeutics Inc Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Adelman Daniel C Md is the Sr. VP & Development and CMO of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Adelman Daniel C Md is the Senior VP,Drug Discovery & Dev of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Adelman Daniel C Md made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 21,403 shares made by Daniel R. Chevallard , a net sale of 4,272 shares made by Lisa Rojkjaer , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 3,405 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 3,405 shares. During the past 18 months, 25,675 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 74,325 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

Adelman Daniel C Md Mailing Address

Above is the net worth, insider trading, and ownership report for Adelman Daniel C Md. You might contact Adelman Daniel C Md via mailing address: 23 Woodleaf Avenue, Redwood City Ca 94061.

Discussions on Adelman Daniel C Md

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.